Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.

Background: Xuezhikang (XZK) is an extract of fermented red yeast rice that has lipid-lowering properties.

Objective: To evaluate the effects of XZK on lipids in subjects with dyslipidemia but no coronary heart disease.

Methods: A total of 116 adults with baseline non-high-density lipoprotein cholesterol (non-HDL-C) levels of approximately 208 mg/dL and low-density lipoprotein cholesterol (LDL-C) levels of approximately 175 mg/dL were randomized to either placebo or XZK 1200 or 2400 mg daily and treated for 12 weeks.

Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.

Aldosterone inhibition with mineralcorticoid receptor antagonists (MRAs) is an effective treatment for resistant hypertension. Aldosterone synthase inhibitors (ASIs) are currently being investigated as a new therapeutic strategy to reduce aldosterone secretion from the adrenal gland. In this study, the efficacy and safety of the first-generation ASI LCI699 (0.